Share on LinkedInShare on LinkedIn

ARTICLE · 03 JUNE 2016

Selected Pharma And Biotech Implications Of CETA And TPP

Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
Contributor
Borden Ladner Gervais LLP

Borden Ladner Gervais LLP

With over 750 lawyers, intellectual property agents and other professionals, BLG services...

View firm profile
Explore more from Borden Ladner Gervais LLP

Recently, Canada has concluded negotiations on two international treaties whose terms will have an effect on patent rights for patentees in Canada.

CanadaIntellectual Property

Recently, Canada has concluded negotiations on two international treaties whose terms will have an effect on patent rights for patentees in Canada.

The Comprehensive Economic and Trade Agreement (CETA) was negotiated between Canada and the European Union. It covers the broad trade relationship Canada has with Europe. Canada's Minister of International Trade released a joint statement with the European Commissioner for Trade, indicating that they expect CETA to be signed in 2016 and enter into force in 2017.1

The Trans-Pacific Partnership (TPP) was negotiated between Australia, Brunei Darussalam, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, the United States, Viet Nam and Canada. Canada's Minister of International Trade has released a statement indicating that it is still too soon to endorse the TPP, but also too soon to close the door. Canada has signed the agreement. However, the Minister maintains that the text will be tabled in Parliament for

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from